Amryt Pharma Share Price (AMYT)

0.00 0.00 (0.00%) delayed: 12:41AM GMT
Bid price 14.00 Open price 0.00
Ask price 14.80 Prev close 14.50
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live Amryt Pharma share prices, Amryt Pharma stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Amryt Pharma Level 2 Data, indepth research tools and investor commentary for Amryt Pharma (AMYT) and other London Stock Exchange equities.

Amryt Pharma Share Price Chart

Advanced Charts >>

Register now for FREE Amryt Pharma share price charts

Amryt Pharma Share Price Information

Name Amryt Pharma Epic AMYT
Sector Pharmaceuticals & Biotechnology ISIN GB00BDD1LS57
Activites Amryt Pharma plc's (formerly Fastnet Equity, formerly Fastnet Oil & Gas plc, formerly Sterling Green Group plc, formerly Hamilton Partners plc) is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments. The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ('bad' cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood. Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis bullosa (EB), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion. Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. Index n/a

Amryt Pharma Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) 47.06
Market Capitalisation (£m) 39.85 Gross Gearing (%) 72.67
Shares in issue (m) 274.82 Debt Ratio 68.86
P/E Ratio -1.24 Debt-to-Equity Ratio 0.83
Total dividends per share (p) 0.00 Assets / Equity Ratio 3.66
Dividend Yield (%) 0.00 Price to book value 1.82
Dividend cover (x) 0.00 ROCE (%) -37.19
Earning per share (p) -11.72 EPS Growth (%) -145.19
52 week high / low 21.50 / 12.35 DPS Growth (%) n/a

Amryt Pharma Director Deals

Dec.Date Type Director Pos No. of Shares
11/10/2017 PLAC Harry Stratford CH 150,000
11/10/2017 PLAC Joe Wiley CEO 221,592
11/10/2017 PLAC Rory Nealon FD 221,592
11/10/2017 PLAC James Culverwell NED 221,592
11/10/2017 PLAC Markus Ziener NED 132,955

More Amryt Pharma Director Deals >>

Amryt Pharma Company News

13:08 10/12/2018

Amryt Pharma consortium wins €8.4m Irish government grant

Amryt Pharma said a consortium it is leading had been awarded grant funding of €8.4m over three years by the Irish government to develop a non-viral gene therapy platform. The grant was part of the government's Disruptive Technologies Innovation Fund. It was awarded a consortium comprised of...

11:30 10/12/2018

Grant Funding from Irish Government for AP103

RNS Number : 9788J Amryt Pharma PLC 10 December 2018   10 December 2018 AIM: AMYT ESM: AYP Amryt Pharma plc ("Amryt" or the "Company")   Grant Funding from Irish Government for AP103   Amryt led consortium to receive €8.4m from Disruptive...

More Amryt Pharma Company News >>

Register now for FREE Amryt Pharma company news

Amryt Pharma Share Price Discussions

No Amryt Pharma Share Price Discussions

Register now for FREE Amryt Pharma share price discussions